Developments in the Management of Metastatic HER2-Positive Breast Cancer and Delivery of Patient-Centered Oncology Care

Program Description
HER2 expression is a marker of more aggressive disease and presents in about 25% of breast cancers. The treatment of HER2-positive breast cancer has evolved with increasing availability of HER2-targeted therapies. The appropriate sequencing of therapies for patients with HER2-positive breast cancer can be complex, and pharmacists are integral to ensuring care coordination and providing medication expertise to the multidisciplinary care team. In this program, expert faculty will review recent clinical trial data and guideline recommendations detailing the use of HER2-targeted therapy for first-line treatment. Patient adherence to therapy remains a priority compounded by cost of treatment and concerns of adverse effects of therapy. To ensure optimal patient outcomes, pharmacists must be prepared to make early interventions and assist the oncology care team with identification and management of potential treatment-related adverse effects of HER2-targeted therapies. Oncology pharmacists are positioned to use information gained through this activity to provide education to patients and members of the health care team, monitor drug toxicities, and recommend dose adjustments as appropriate.

Target audience: Health-system pharmacists, oncology pharmacists, specialty pharmacists, physicians, and nurses.

Type of activity: Application
Release date: January 31, 2022
Expiration date: January 31, 2023
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Compare the mechanisms of action and administration of HER2-targeted therapies
• Interpret recent literature evaluating therapies in HER2-positive metastatic breast cancer and subsequent implications for changes in practice paradigms
• Identify adverse effect profiles and management strategies in efforts to improve adherence to and patient outcomes associated with HER2-targeted therapy

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-049-L01-P. The activity is available for CE credit through January 31, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Danielle Roman, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms